Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Shield Therapeutics ( (GB:STX) ) is now available.
Shield Therapeutics has announced that its issued share capital now comprises 1,067,997,016 ordinary shares of 1.5p each, all carrying equal voting rights and with no shares held in treasury. This updated total voting rights figure provides the new denominator for shareholders and investors to assess and disclose changes in their ownership stakes under UK regulatory transparency requirements, reinforcing clarity around the company’s capital structure in the market.
The most recent analyst rating on (GB:STX) stock is a Hold with a £10.50 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Spark’s Take on GB:STX Stock
According to Spark, TipRanks’ AI Analyst, GB:STX is a Neutral.
The overall stock score is primarily influenced by the company’s robust technical momentum and positive corporate events, which are offset by significant financial challenges and valuation concerns. The strong technical indicators and strategic corporate developments provide optimism, but financial instability remains a critical risk.
To see Spark’s full report on GB:STX stock, click here.
More about Shield Therapeutics
Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on treating iron deficiency with or without anemia through its innovative oral iron therapy ACCRUFeR/FeRACCRU (ferric maltol). The company has launched ACCRUFeR in the U.S. via an exclusive multi-year collaboration with Viatris and has out-licensed commercialization rights to partners across Europe, the UK, Australia, New Zealand, China, Hong Kong, Macau, Taiwan, South Korea, Canada, and Japan, targeting a large and growing global iron deficiency market.
Average Trading Volume: 2,917,199
Technical Sentiment Signal: Buy
Current Market Cap: £109.9M
Learn more about STX stock on TipRanks’ Stock Analysis page.